Biocartis Group NV
Biocartis Group NV (BIOGF) Stock Competitors & Peer Comparison
See (BIOGF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOGF | $0.66 | -85.33% | 65.4M | -0.67 | -$0.98 | N/A |
| WUXAY | $16.11 | +0.00% | 46.4B | 15.79 | $1.02 | +1.74% |
| LZAGF | $625.45 | -3.06% | 45.8B | 39.63 | $16.53 | +0.52% |
| LZAGY | $62.67 | -1.74% | 44.6B | 38.03 | $1.65 | +0.90% |
| WUXIF | $13.88 | +0.00% | 41.4B | 13.74 | $1.01 | +3.51% |
| ERFSF | $74.19 | +0.60% | 12.8B | 24.72 | $2.96 | +1.15% |
| BMXMF | $87.42 | +7.03% | 10.3B | 22.53 | $3.88 | +1.26% |
| BMXXY | $8.30 | +0.00% | 9.8B | 21.28 | $0.39 | +1.24% |
| SKHHY | $13.32 | +0.23% | 6.6B | 16.91 | $0.79 | +5.50% |
| HNGZY | $4.00 | +0.00% | 6.2B | 26.67 | $0.15 | +0.72% |
Stock Comparison
BIOGF vs WUXAY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, WUXAY has a market cap of 46.4B. Regarding current trading prices, BIOGF is priced at $0.66, while WUXAY trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas WUXAY's P/E ratio is 15.79. In terms of profitability, BIOGF's ROE is +2.04%, compared to WUXAY's ROE of +0.27%. Regarding short-term risk, BIOGF is less volatile compared to WUXAY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check WUXAY's competition here
BIOGF vs LZAGF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, LZAGF has a market cap of 45.8B. Regarding current trading prices, BIOGF is priced at $0.66, while LZAGF trades at $625.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas LZAGF's P/E ratio is 39.63. In terms of profitability, BIOGF's ROE is +2.04%, compared to LZAGF's ROE of +0.10%. Regarding short-term risk, BIOGF is less volatile compared to LZAGF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check LZAGF's competition here
BIOGF vs LZAGY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, LZAGY has a market cap of 44.6B. Regarding current trading prices, BIOGF is priced at $0.66, while LZAGY trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas LZAGY's P/E ratio is 38.03. In terms of profitability, BIOGF's ROE is +2.04%, compared to LZAGY's ROE of +0.10%. Regarding short-term risk, BIOGF is less volatile compared to LZAGY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check LZAGY's competition here
BIOGF vs WUXIF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, BIOGF is priced at $0.66, while WUXIF trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas WUXIF's P/E ratio is 13.74. In terms of profitability, BIOGF's ROE is +2.04%, compared to WUXIF's ROE of +0.27%. Regarding short-term risk, BIOGF is less volatile compared to WUXIF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check WUXIF's competition here
BIOGF vs ERFSF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ERFSF has a market cap of 12.8B. Regarding current trading prices, BIOGF is priced at $0.66, while ERFSF trades at $74.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ERFSF's P/E ratio is 24.72. In terms of profitability, BIOGF's ROE is +2.04%, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, BIOGF is less volatile compared to ERFSF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check ERFSF's competition here
BIOGF vs BMXMF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, BMXMF has a market cap of 10.3B. Regarding current trading prices, BIOGF is priced at $0.66, while BMXMF trades at $87.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas BMXMF's P/E ratio is 22.53. In terms of profitability, BIOGF's ROE is +2.04%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, BIOGF is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check BMXMF's competition here
BIOGF vs BMXXY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, BMXXY has a market cap of 9.8B. Regarding current trading prices, BIOGF is priced at $0.66, while BMXXY trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas BMXXY's P/E ratio is 21.28. In terms of profitability, BIOGF's ROE is +2.04%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, BIOGF is less volatile compared to BMXXY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check BMXXY's competition here
BIOGF vs SKHHY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, SKHHY has a market cap of 6.6B. Regarding current trading prices, BIOGF is priced at $0.66, while SKHHY trades at $13.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas SKHHY's P/E ratio is 16.91. In terms of profitability, BIOGF's ROE is +2.04%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, BIOGF is less volatile compared to SKHHY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check SKHHY's competition here
BIOGF vs HNGZY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, BIOGF is priced at $0.66, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, BIOGF's ROE is +2.04%, compared to HNGZY's ROE of +0.04%. Regarding short-term risk, BIOGF is less volatile compared to HNGZY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check HNGZY's competition here
BIOGF vs SKHCF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, SKHCF has a market cap of 5.9B. Regarding current trading prices, BIOGF is priced at $0.66, while SKHCF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas SKHCF's P/E ratio is 15.19. In terms of profitability, BIOGF's ROE is +2.04%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, BIOGF is less volatile compared to SKHCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check SKHCF's competition here
BIOGF vs DSRLF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, DSRLF has a market cap of 3.6B. Regarding current trading prices, BIOGF is priced at $0.66, while DSRLF trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas DSRLF's P/E ratio is 21.82. In terms of profitability, BIOGF's ROE is +2.04%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, BIOGF and DSRLF have similar daily volatility (0.00).Check DSRLF's competition here
BIOGF vs TCGGY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, BIOGF is priced at $0.66, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, BIOGF's ROE is +2.04%, compared to TCGGY's ROE of -0.09%. Regarding short-term risk, BIOGF is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check TCGGY's competition here
BIOGF vs TCHBF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, TCHBF has a market cap of 2.2B. Regarding current trading prices, BIOGF is priced at $0.66, while TCHBF trades at $177.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas TCHBF's P/E ratio is -15.95. In terms of profitability, BIOGF's ROE is +2.04%, compared to TCHBF's ROE of -0.09%. Regarding short-term risk, BIOGF and TCHBF have similar daily volatility (0.00).Check TCHBF's competition here
BIOGF vs STSEY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, STSEY has a market cap of 1.7B. Regarding current trading prices, BIOGF is priced at $0.66, while STSEY trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas STSEY's P/E ratio is -78.71. In terms of profitability, BIOGF's ROE is +2.04%, compared to STSEY's ROE of -0.01%. Regarding short-term risk, BIOGF and STSEY have similar daily volatility (0.00).Check STSEY's competition here
BIOGF vs VIMGF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, BIOGF is priced at $0.66, while VIMGF trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, BIOGF's ROE is +2.04%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, BIOGF is less volatile compared to VIMGF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check VIMGF's competition here
BIOGF vs GNTLF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, BIOGF is priced at $0.66, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, BIOGF's ROE is +2.04%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, BIOGF and GNTLF have similar daily volatility (0.00).Check GNTLF's competition here
BIOGF vs MRCHF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, MRCHF has a market cap of 1.1B. Regarding current trading prices, BIOGF is priced at $0.66, while MRCHF trades at $19.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas MRCHF's P/E ratio is 25.07. In terms of profitability, BIOGF's ROE is +2.04%, compared to MRCHF's ROE of +0.05%. Regarding short-term risk, BIOGF and MRCHF have similar daily volatility (0.00).Check MRCHF's competition here
BIOGF vs IDGXF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IDGXF has a market cap of 345.7M. Regarding current trading prices, BIOGF is priced at $0.66, while IDGXF trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IDGXF's P/E ratio is 11.89. In terms of profitability, BIOGF's ROE is +2.04%, compared to IDGXF's ROE of +0.42%. Regarding short-term risk, BIOGF is less volatile compared to IDGXF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check IDGXF's competition here
BIOGF vs EDTXF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, EDTXF has a market cap of 295.1M. Regarding current trading prices, BIOGF is priced at $0.66, while EDTXF trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas EDTXF's P/E ratio is -11.18. In terms of profitability, BIOGF's ROE is +2.04%, compared to EDTXF's ROE of +0.61%. Regarding short-term risk, BIOGF and EDTXF have similar daily volatility (0.00).Check EDTXF's competition here
BIOGF vs PFGTF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, PFGTF has a market cap of 197.6M. Regarding current trading prices, BIOGF is priced at $0.66, while PFGTF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas PFGTF's P/E ratio is -9.66. In terms of profitability, BIOGF's ROE is +2.04%, compared to PFGTF's ROE of -1.30%. Regarding short-term risk, BIOGF and PFGTF have similar daily volatility (0.00).Check PFGTF's competition here
BIOGF vs AMCY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, BIOGF is priced at $0.66, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas AMCY's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to AMCY's ROE of N/A. Regarding short-term risk, BIOGF and AMCY have similar daily volatility (0.00).Check AMCY's competition here
BIOGF vs NNGRF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, BIOGF is priced at $0.66, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, BIOGF's ROE is +2.04%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, BIOGF and NNGRF have similar daily volatility (0.00).Check NNGRF's competition here
BIOGF vs DIUXF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, DIUXF has a market cap of 141.3M. Regarding current trading prices, BIOGF is priced at $0.66, while DIUXF trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas DIUXF's P/E ratio is -83.50. In terms of profitability, BIOGF's ROE is +2.04%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, BIOGF is less volatile compared to DIUXF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check DIUXF's competition here
BIOGF vs CORBF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, CORBF has a market cap of 127.2M. Regarding current trading prices, BIOGF is priced at $0.66, while CORBF trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas CORBF's P/E ratio is 2.71. In terms of profitability, BIOGF's ROE is +2.04%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, BIOGF and CORBF have similar daily volatility (0.00).Check CORBF's competition here
BIOGF vs THOXF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, BIOGF is priced at $0.66, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas THOXF's P/E ratio is -7.45. In terms of profitability, BIOGF's ROE is +2.04%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, BIOGF is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check THOXF's competition here
BIOGF vs TIHE Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, BIOGF is priced at $0.66, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas TIHE's P/E ratio is 0.32. In terms of profitability, BIOGF's ROE is +2.04%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, BIOGF and TIHE have similar daily volatility (0.00).Check TIHE's competition here
BIOGF vs PCNEF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, BIOGF is priced at $0.66, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, BIOGF's ROE is +2.04%, compared to PCNEF's ROE of -0.05%. Regarding short-term risk, BIOGF is less volatile compared to PCNEF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check PCNEF's competition here
BIOGF vs LDXHF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, LDXHF has a market cap of 61.1M. Regarding current trading prices, BIOGF is priced at $0.66, while LDXHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas LDXHF's P/E ratio is -8.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, BIOGF is less volatile compared to LDXHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check LDXHF's competition here
BIOGF vs BMKDF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, BMKDF has a market cap of 46.2M. Regarding current trading prices, BIOGF is priced at $0.66, while BMKDF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas BMKDF's P/E ratio is -43.96. In terms of profitability, BIOGF's ROE is +2.04%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, BIOGF and BMKDF have similar daily volatility (0.00).Check BMKDF's competition here
BIOGF vs BIOQ Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, BIOQ has a market cap of 31.3M. Regarding current trading prices, BIOGF is priced at $0.66, while BIOQ trades at $35.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas BIOQ's P/E ratio is 15.84. In terms of profitability, BIOGF's ROE is +2.04%, compared to BIOQ's ROE of -0.03%. Regarding short-term risk, BIOGF and BIOQ have similar daily volatility (0.00).Check BIOQ's competition here
BIOGF vs ABDXF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ABDXF has a market cap of 30.3M. Regarding current trading prices, BIOGF is priced at $0.66, while ABDXF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ABDXF's P/E ratio is -16.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, BIOGF and ABDXF have similar daily volatility (0.00).Check ABDXF's competition here
BIOGF vs SNANF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, SNANF has a market cap of 27.7M. Regarding current trading prices, BIOGF is priced at $0.66, while SNANF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas SNANF's P/E ratio is -12.10. In terms of profitability, BIOGF's ROE is +2.04%, compared to SNANF's ROE of -10.44%. Regarding short-term risk, BIOGF is less volatile compared to SNANF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check SNANF's competition here
BIOGF vs ANPCY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, BIOGF is priced at $0.66, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, BIOGF's ROE is +2.04%, compared to ANPCY's ROE of -0.90%. Regarding short-term risk, BIOGF is less volatile compared to ANPCY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check ANPCY's competition here
BIOGF vs PCHM Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, BIOGF is priced at $0.66, while PCHM trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas PCHM's P/E ratio is -0.02. In terms of profitability, BIOGF's ROE is +2.04%, compared to PCHM's ROE of +0.25%. Regarding short-term risk, BIOGF is less volatile compared to PCHM. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check PCHM's competition here
BIOGF vs VILGF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, BIOGF is priced at $0.66, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas VILGF's P/E ratio is -0.30. In terms of profitability, BIOGF's ROE is +2.04%, compared to VILGF's ROE of N/A. Regarding short-term risk, BIOGF and VILGF have similar daily volatility (0.00).Check VILGF's competition here
BIOGF vs CLIFF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, CLIFF has a market cap of 18M. Regarding current trading prices, BIOGF is priced at $0.66, while CLIFF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas CLIFF's P/E ratio is -1.76. In terms of profitability, BIOGF's ROE is +2.04%, compared to CLIFF's ROE of -0.11%. Regarding short-term risk, BIOGF is less volatile compared to CLIFF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check CLIFF's competition here
BIOGF vs LDDD Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, LDDD has a market cap of 15.3M. Regarding current trading prices, BIOGF is priced at $0.66, while LDDD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas LDDD's P/E ratio is -51.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to LDDD's ROE of -0.36%. Regarding short-term risk, BIOGF is less volatile compared to LDDD. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check LDDD's competition here
BIOGF vs IZOZF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IZOZF has a market cap of 12.9M. Regarding current trading prices, BIOGF is priced at $0.66, while IZOZF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IZOZF's P/E ratio is -9.33. In terms of profitability, BIOGF's ROE is +2.04%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, BIOGF is less volatile compared to IZOZF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check IZOZF's competition here
BIOGF vs MXDHF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, BIOGF is priced at $0.66, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, BIOGF's ROE is +2.04%, compared to MXDHF's ROE of +4.03%. Regarding short-term risk, BIOGF and MXDHF have similar daily volatility (0.00).Check MXDHF's competition here
BIOGF vs JMPHF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, JMPHF has a market cap of 8.1M. Regarding current trading prices, BIOGF is priced at $0.66, while JMPHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas JMPHF's P/E ratio is 4.28. In terms of profitability, BIOGF's ROE is +2.04%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, BIOGF is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check JMPHF's competition here
BIOGF vs IDXG Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IDXG has a market cap of 8.1M. Regarding current trading prices, BIOGF is priced at $0.66, while IDXG trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IDXG's P/E ratio is 2.09. In terms of profitability, BIOGF's ROE is +2.04%, compared to IDXG's ROE of +2.15%. Regarding short-term risk, BIOGF and IDXG have similar daily volatility (0.00).Check IDXG's competition here
BIOGF vs ANPCF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ANPCF has a market cap of 6.5M. Regarding current trading prices, BIOGF is priced at $0.66, while ANPCF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ANPCF's P/E ratio is -0.33. In terms of profitability, BIOGF's ROE is +2.04%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, BIOGF is less volatile compared to ANPCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check ANPCF's competition here
BIOGF vs IMMVF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, BIOGF is priced at $0.66, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, BIOGF's ROE is +2.04%, compared to IMMVF's ROE of -3.53%. Regarding short-term risk, BIOGF is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check IMMVF's competition here
BIOGF vs SQIDF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, BIOGF is priced at $0.66, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, BIOGF's ROE is +2.04%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, BIOGF is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check SQIDF's competition here
BIOGF vs PMSNF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, PMSNF has a market cap of 5.8M. Regarding current trading prices, BIOGF is priced at $0.66, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to PMSNF's ROE of +0.34%. Regarding short-term risk, BIOGF and PMSNF have similar daily volatility (0.00).Check PMSNF's competition here
BIOGF vs VRCDF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, BIOGF is priced at $0.66, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, BIOGF's ROE is +2.04%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, BIOGF is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check VRCDF's competition here
BIOGF vs RNVA Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, BIOGF is priced at $0.66, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas RNVA's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, BIOGF and RNVA have similar daily volatility (0.00).Check RNVA's competition here
BIOGF vs TDSGF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, TDSGF has a market cap of 4M. Regarding current trading prices, BIOGF is priced at $0.66, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas TDSGF's P/E ratio is -4.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, BIOGF and TDSGF have similar daily volatility (0.00).Check TDSGF's competition here
BIOGF vs AVCRF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, AVCRF has a market cap of 3.3M. Regarding current trading prices, BIOGF is priced at $0.66, while AVCRF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas AVCRF's P/E ratio is -3.24. In terms of profitability, BIOGF's ROE is +2.04%, compared to AVCRF's ROE of -1.41%. Regarding short-term risk, BIOGF is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check AVCRF's competition here
BIOGF vs ICBU Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ICBU has a market cap of 3M. Regarding current trading prices, BIOGF is priced at $0.66, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ICBU's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to ICBU's ROE of -0.22%. Regarding short-term risk, BIOGF is less volatile compared to ICBU. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check ICBU's competition here
BIOGF vs IBXXF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IBXXF has a market cap of 2.2M. Regarding current trading prices, BIOGF is priced at $0.66, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IBXXF's P/E ratio is -1.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, BIOGF is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check IBXXF's competition here
BIOGF vs CHHL Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, BIOGF is priced at $0.66, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas CHHL's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, BIOGF is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check CHHL's competition here
BIOGF vs IVRO Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IVRO has a market cap of 1.7M. Regarding current trading prices, BIOGF is priced at $0.66, while IVRO trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IVRO's P/E ratio is -0.77. In terms of profitability, BIOGF's ROE is +2.04%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, BIOGF and IVRO have similar daily volatility (0.00).Check IVRO's competition here
BIOGF vs SLDX Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, SLDX has a market cap of 1.4M. Regarding current trading prices, BIOGF is priced at $0.66, while SLDX trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas SLDX's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to SLDX's ROE of +0.17%. Regarding short-term risk, BIOGF and SLDX have similar daily volatility (0.00).Check SLDX's competition here
BIOGF vs DIGP Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, BIOGF is priced at $0.66, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas DIGP's P/E ratio is -1.04. In terms of profitability, BIOGF's ROE is +2.04%, compared to DIGP's ROE of +0.96%. Regarding short-term risk, BIOGF is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check DIGP's competition here
BIOGF vs EPGNF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, BIOGF is priced at $0.66, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, BIOGF's ROE is +2.04%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, BIOGF and EPGNF have similar daily volatility (0.00).Check EPGNF's competition here
BIOGF vs RSHN Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, BIOGF is priced at $0.66, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas RSHN's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, BIOGF is less volatile compared to RSHN. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check RSHN's competition here
BIOGF vs IDTA Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IDTA has a market cap of 716.1K. Regarding current trading prices, BIOGF is priced at $0.66, while IDTA trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IDTA's P/E ratio is 4.43. In terms of profitability, BIOGF's ROE is +2.04%, compared to IDTA's ROE of +0.24%. Regarding short-term risk, BIOGF is less volatile compared to IDTA. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check IDTA's competition here
BIOGF vs SZLSF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, BIOGF is priced at $0.66, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, BIOGF's ROE is +2.04%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, BIOGF is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check SZLSF's competition here
BIOGF vs SCRSF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, BIOGF is priced at $0.66, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, BIOGF's ROE is +2.04%, compared to SCRSF's ROE of +2.02%. Regarding short-term risk, BIOGF and SCRSF have similar daily volatility (0.00).Check SCRSF's competition here
BIOGF vs NSTM Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, BIOGF is priced at $0.66, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas NSTM's P/E ratio is 0.20. In terms of profitability, BIOGF's ROE is +2.04%, compared to NSTM's ROE of -1.25%. Regarding short-term risk, BIOGF is less volatile compared to NSTM. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check NSTM's competition here
BIOGF vs MBGNF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, BIOGF is priced at $0.66, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, BIOGF's ROE is +2.04%, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, BIOGF is less volatile compared to MBGNF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check MBGNF's competition here
BIOGF vs NVTAQ Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, BIOGF is priced at $0.66, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, BIOGF is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check NVTAQ's competition here
BIOGF vs HCLC Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, BIOGF is priced at $0.66, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas HCLC's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, BIOGF and HCLC have similar daily volatility (0.00).Check HCLC's competition here
BIOGF vs MEDD Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, MEDD has a market cap of 31.9K. Regarding current trading prices, BIOGF is priced at $0.66, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas MEDD's P/E ratio is -0.01. In terms of profitability, BIOGF's ROE is +2.04%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, BIOGF and MEDD have similar daily volatility (0.00).Check MEDD's competition here
BIOGF vs TOMDF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, BIOGF is priced at $0.66, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas TOMDF's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, BIOGF is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check TOMDF's competition here
BIOGF vs CGNH Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, BIOGF is priced at $0.66, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas CGNH's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, BIOGF and CGNH have similar daily volatility (0.00).Check CGNH's competition here
BIOGF vs ARYC Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ARYC has a market cap of 7.9K. Regarding current trading prices, BIOGF is priced at $0.66, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ARYC's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, BIOGF is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check ARYC's competition here
BIOGF vs ABMC Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, BIOGF is priced at $0.66, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ABMC's P/E ratio is 0.01. In terms of profitability, BIOGF's ROE is +2.04%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, BIOGF and ABMC have similar daily volatility (0.00).Check ABMC's competition here
BIOGF vs CYPS Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, BIOGF is priced at $0.66, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas CYPS's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to CYPS's ROE of N/A. Regarding short-term risk, BIOGF and CYPS have similar daily volatility (0.00).Check CYPS's competition here
BIOGF vs RGDXQ Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, BIOGF is priced at $0.66, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, BIOGF is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check RGDXQ's competition here
BIOGF vs DMTKQ Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, BIOGF is priced at $0.66, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, BIOGF and DMTKQ have similar daily volatility (0.00).Check DMTKQ's competition here
BIOGF vs MEDVF Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, BIOGF is priced at $0.66, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas MEDVF's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, BIOGF is less volatile compared to MEDVF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check MEDVF's competition here
BIOGF vs IHTI Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, IHTI has a market cap of 1.6K. Regarding current trading prices, BIOGF is priced at $0.66, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas IHTI's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, BIOGF is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check IHTI's competition here
BIOGF vs GWHP Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, BIOGF is priced at $0.66, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas GWHP's P/E ratio is -0.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, BIOGF is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check GWHP's competition here
BIOGF vs ROSGQ Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, BIOGF is priced at $0.66, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, BIOGF and ROSGQ have similar daily volatility (0.00).Check ROSGQ's competition here
BIOGF vs BIOCQ Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, BIOGF is priced at $0.66, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, BIOGF and BIOCQ have similar daily volatility (0.00).Check BIOCQ's competition here
BIOGF vs HTGMQ Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, BIOGF is priced at $0.66, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, BIOGF and HTGMQ have similar daily volatility (0.00).Check HTGMQ's competition here
BIOGF vs OPGX Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, OPGX has a market cap of 17. Regarding current trading prices, BIOGF is priced at $0.66, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas OPGX's P/E ratio is -0.00. In terms of profitability, BIOGF's ROE is +2.04%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, BIOGF is less volatile compared to OPGX. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGF.Check OPGX's competition here
BIOGF vs BGNX Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, BGNX has a market cap of 0. Regarding current trading prices, BIOGF is priced at $0.66, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas BGNX's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to BGNX's ROE of N/A. Regarding short-term risk, BIOGF and BGNX have similar daily volatility (0.00).Check BGNX's competition here
BIOGF vs MRPS Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, MRPS has a market cap of 0. Regarding current trading prices, BIOGF is priced at $0.66, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas MRPS's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to MRPS's ROE of N/A. Regarding short-term risk, BIOGF and MRPS have similar daily volatility (0.00).Check MRPS's competition here
BIOGF vs EPGNY Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, BIOGF is priced at $0.66, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, BIOGF's ROE is +2.04%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, BIOGF and EPGNY have similar daily volatility (0.00).Check EPGNY's competition here
BIOGF vs AGHC Comparison May 2026
BIOGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGF stands at 65.4M. In comparison, AGHC has a market cap of 0. Regarding current trading prices, BIOGF is priced at $0.66, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGF currently has a P/E ratio of -0.67, whereas AGHC's P/E ratio is N/A. In terms of profitability, BIOGF's ROE is +2.04%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, BIOGF and AGHC have similar daily volatility (0.00).Check AGHC's competition here